Bimatoprost vs latanoprost

Patients on latanoprost monotherapy who required additional IOP lowering discontinued latanoprost and were randomized to bimatoprost 0.03%

travoprost (Travatan) versus latanoprost solution (Xalatan) versus bimatoprost. (Lumigan). Travoprost 0.004%, bimatoprost 0.03%, and

Latanoprost is more susceptible to degradation at elevated temperature than bimatoprost. Bimatoprost also has the advantage of being available as a powder

Efficacy and tolerability of bimatoprost vs travoprost in patients previously on latanoprost: a three-month, randomized, masked-evaluator, multicentre study

by I DERMATOLOGICAL Cited by 3BIMATOPROST VERSUS LATANOPROST. PLUS ADJUNCTIVE PRODUCTS FOR. GLAUCOMA $784 per successfully treated patient for bimatoprost vs. the latanoprost plus

latanoprost, travoprost, bimatoprost, and latanoprost versus travoprost : results of an on hypotensive effect of latanoprost vs timolol

Since the introduction of latanoprost, additional PGs have become available, including travoprost (Travatan) and bimatoprost (Lumigan). Both latanoprost and bimatoprost are listed on the drug s package insert as capable of being a primary agent.

bimatoprost (Lumigan, Bimatoprost Actavis); latanoprost (Hysite); travoprost (Travatan, Travopt). Possible side effects include: changes in

latanoprost vs bimatoprost), fewer reported hyperemia (P.001, latanoprost vs bimatoprost), and average hyper-emia scores were lower at week 12 (P.001, latano-prost vs bimatoprost). CONCLUSIONS: Latanoprost, bimatoprost, and tra-voprost were comparable in their ability to reduce IOP in OAG and OH patients. Latanoprost exhibited greater